Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Prolonged course of two antibiotics treats recurrent and refractory pouchitis effectively

Four-week treatment with a combination of metronidazole and ciprofloxacin improves inflammation and quality of life in patients with active recurrent or refractory pouchitis, according to research published in the May issue of Alimentary Pharmacology and Therapeutics.

News image

fiogf49gjkf04

Researchers from England, Italy, and Germany evaluated the therapeutic efficacy of a prolonged course of a combination of two antibiotics in patients with refractory or recurrent pouchitis.

They also assessed its impact on their quality of life.

Patients recruited had a history of pouchitis at least twice in the last 12 months or persistent pouchitis requiring continual intake of antibiotics. They also had a Pouchitis Disease Activity Index score of 7 (best to worst pouchitis = 0-18) at the beginning of therapy.

Treatment consisted of a combination of metronidazole, 400 or 500 mg twice daily, and ciprofloxacin, 500 mg twice daily, for 28 days.

Symptomatic, endoscopic, and histological evaluations were undertaken before and after antibiotic therapy using the Pouchitis Disease Activity Index score.

Remission was defined as a combination of a Pouchitis Disease Activity Index clinical score of ≤2, endoscopic score of ≤1, and total score of ≤4.

The quality of life was assessed with the Inflammatory Bowel Disease Questionnaire, which encompasses bowel, systemic, and emotional symptoms, as well as social function (worst to best = 32-224).

A total of 44 patients (24 men, median age of 38 years) entered the trial and completed treatment.

82% went into remission after 4-week course of metronidazole and ciprofloxacin.
Alimentary Pharmacology and Therapeutics
Of these, 82% went into remission.

The median Pouchitis Disease Activity Index scores before and after therapy were 12 and 3, respectively.

The researchers found that the median Inflammatory Bowel Disease Questionnaire score also significantly improved from 97 to 175 with this therapy.

The 8 patients (5 male) who did not go into remission were significantly older (median 48 vs 35 years) and had a longer history of pouchitis (96 vs 26 months), than those who went into remission.

They also had a greater proportion with chronic pouchitis (chronic/relapsing: 6/2 vs 9/27; relative risk, 1.6) and tended to have a higher Pouchitis Disease Activity Index score before treatment (median 15 vs 12)

Even in these 8 patients, the median Pouchitis Disease Activity Index score significantly improved from 15 to 10, as did the Inflammatory Bowel Disease Questionnaire score from 96 to 127.

The Inflammatory Bowel Disease Questionnaire score was found to strongly correlate with the Pouchitis Disease Activity Index score. It was also significantly related to the patients' overall assessment of satisfaction.

No serious side-effects were noted.

Author T. Mimura, of St Mark's Hospital, London, England, said on behalf of the group, "Four-week treatment with a combination of metronidazole and ciprofloxacin is highly effective in patients with active recurrent or refractory pouchitis, objectively improving the inflammation and quality of life."

"The Inflammatory Bowel Disease Questionnaire is a sensitive tool for evaluating patients with pouchitis, and correlates well with disease activity," it was concluded.

Aliment Pharmacol Ther 2002; 16(5): 909-17
24 April 2002

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us